SLC25A1 and metabolic dysfunction-associated steatohepatitis: Meanwhile, as a specific inhibitor of SLC25A1, CTPI-2 significantly mitigates lipid metabolism disorders in non-alcoholic steatohepatitis (NASH), thereby impeding its progression to hepatic steatosis and reducing inflammatory macrophage infiltration in the liver and adipose tissue (58).